Alector (NASDAQ:ALEC) CFO Neil Lindsay Berkley Sells 19,360 Shares

Alector, Inc. (NASDAQ:ALEC) CFO Neil Lindsay Berkley sold 19,360 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total value of $38,139.20. Following the completion of the transaction, the chief financial officer directly owned 379,900 shares of the company’s stock, valued at approximately $748,403. This trade represents a 4.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Alector Trading Down 9.0%

Alector stock opened at $1.78 on Thursday. The business has a 50 day moving average price of $2.29 and a two-hundred day moving average price of $1.94. The company has a quick ratio of 5.25, a current ratio of 5.25 and a debt-to-equity ratio of 0.80. The stock has a market cap of $197.08 million, a price-to-earnings ratio of -1.49 and a beta of 0.61. Alector, Inc. has a 12 month low of $1.09 and a 12 month high of $3.40.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $9.67 million. Alector had a negative return on equity of 295.17% and a negative net margin of 680.83%. As a group, equities analysts forecast that Alector, Inc. will post -0.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ALEC shares. BTIG Research raised Alector from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Tuesday, March 10th. Morgan Stanley reissued an “underweight” rating and issued a $2.00 price target on shares of Alector in a research report on Monday, May 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alector in a research report on Monday, May 4th. Wall Street Zen raised shares of Alector from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Cantor Fitzgerald raised shares of Alector from a “neutral” rating to an “overweight” rating in a research report on Wednesday, April 15th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.63.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Lexington Partners L.P. acquired a new position in Alector in the third quarter worth about $30,000. Savant Capital LLC acquired a new stake in shares of Alector during the third quarter worth approximately $35,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Alector during the third quarter worth approximately $37,000. Bronte Capital Management Pty Ltd. acquired a new stake in shares of Alector during the fourth quarter worth approximately $30,000. Finally, Hershey Trust Co. increased its holdings in shares of Alector by 100.0% during the fourth quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock worth $32,000 after buying an additional 10,286 shares in the last quarter. Institutional investors and hedge funds own 85.83% of the company’s stock.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.